{"product_id":"hca-vegfr-2-in-3-bhb20443958","title":"hCA\/VEGFR-2-IN-3","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003ch2\u003eCompound Overview\u003c\/h2\u003e\n  \u003cp\u003e\u003cstrong\u003ehCA\/VEGFR-2-IN-3\u003c\/strong\u003e is a research-grade small molecule supplied by TargetMol.\u003c\/p\u003e\n\n  \u003ch2\u003ePhysical Properties\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular Formula\u003c\/th\u003e\n\u003ctd\u003eC24H28N6O6S\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular Weight\u003c\/th\u003e\n\u003ctd\u003e528.58 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eForm\u003c\/th\u003e\n\u003ctd\u003eSolid\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003eRoom Temperature (RT)\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n  \u003ch2\u003eBiological Activity\u003c\/h2\u003e\n  \u003cp\u003ehCA\/VEGFR-2-IN-3 (compound 8j) is an indolinonylbenzenesulfonamide with potential as a dual inhibitor of cancer-associated hCA IX\/XII and VEGFR-2. This compound inhibits VEGFR-2 with an IC50 of 358 nM and exhibits high affinity for hCAs, evidenced by Ki values of 4.2 nM for hCA IX, 22.9 nM for hCA II, 25.1 nM for hCA I, and 28.0 nM for hCA XII. Additionally, hCA\/VEGFR-2-IN-3 demonstrates antiproliferative activity specifically against breast cancer cells that overexpress VEGFR-2 (1).\u003c\/p\u003e\n  \u003cp\u003e\u003cstrong\u003eTarget(s):\u003c\/strong\u003e VEGFR\u003c\/p\u003e\n  \u003cp\u003e\u003cstrong\u003eSignaling pathway(s):\u003c\/strong\u003e Angiogenesis, Tyrosine Kinase\/Adaptors\u003c\/p\u003e\n  \u003ch2\u003eSafety \u0026amp; Regulatory\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for therapeutic, diagnostic, or clinical use. Wear appropriate PPE and consult the Safety Data Sheet (SDS) prior to handling.\u003c\/p\u003e\n  \u003c\/div\u003e\n\u003c\/div\u003e","brand":"TargetMol","offers":[{"title":"5 mg","offer_id":53327279096173,"sku":"T79588-5MG","price":0.0,"currency_code":"USD","in_stock":true},{"title":"50 mg","offer_id":53327606907245,"sku":"T79588-50MG","price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.ebiohippo.com\/products\/hca-vegfr-2-in-3-bhb20443958","provider":"BioHippo","version":"1.0","type":"link"}